Trofosfamide
Chemical compound
- L01AA07 (WHO)
- N,N,3-tris(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amide 2-oxide
- 22089-22-1 Y
- 65702
- 59129 N
- H64JRU6GJ0
- D07252 Y
- ChEMBL462019 N
- DTXSID60865031
- Interactive image
- C1CN(P(=O)(OC1)N(CCCl)CCCl)CCCl
InChI
- InChI=1S/C9H18Cl3N2O2P/c10-2-6-13-5-1-9-16-17(13,15)14(7-3-11)8-4-12/h1-9H2 N
- Key:UMKFEPPTGMDVMI-UHFFFAOYSA-N N
Trofosfamide (INN) is a nitrogen mustard alkylating agent. It is sometimes abbreviated "TRO".[1] It has been used in trials to study its effects on ependymoma, medulloblastoma, sarcoma, soft tissue,[clarification needed] supratentorial PNET, and recurrent brain tumors.[2]
References
- v
- t
- e
(M phase)
Block microtubule assembly | |
---|---|
Block microtubule disassembly |
inhibitor
DNA precursors/ antimetabolites (S phase) |
| ||||||||
---|---|---|---|---|---|---|---|---|---|
Topoisomerase inhibitors (S phase) |
| ||||||||
Crosslinking of DNA (CCNS) |
|
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e